Evaluation Advisory Committee Meeting
5 July 2012
EAC -2012 -Mtg -3a 1




GAVI Alliance Evaluation Advisory Committee Meeting
5 July 2012
Geneva, Switzerland


FINAL MINUTES


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 09.45
Geneva time on 5 July 2012. Sania Nishtar , Committee Chair, participating by
videoconference, chaired the meeting. Rob Moodie co -chaired.

1.2 Standing declarations of interest were tabled to the Committe e (Doc 1a ). Alan
Hinman noted that the Novartis research grant reported was for rabies rather
than measles.

1. 3 The Committee noted the minutes of its meeting of 19 -20 January 2012 in
Geneva (Doc 1b) and its teleconference of 13 February 2012 (Doc 1c) .
The se minutes were approved by no objection on 23 April 201 2.

1.4 The Chair updated the EAC on the GAVI Alliance Board meeting which had
taken place in Washington D.C. in June 2012 and at which she had reported
on the activities of the EAC. The Board had approved the Evaluation Policy
and considered the EAC engagement with the evaluation of GAVI support to
CSOs as quite productive. She had updated the Board on the EAC?s role in
reviewing and approving the Request for Proposals for the Advance Market
Commit ment for Pneumococcal Vaccine Process and Design Evaluation , as
well as the process in relation to the Full Country Evaluations.

1.5 During a short meeting with Dagfinn H ?ybr ?ten, GAVI Alliance Board Chair,
the EAC Chair had briefly discussed the w ork of the EAC feeding into policy
as well as the changing landscape of health with respect to the post MDG
landscape. A short discussion on the latter is recorded under Item 9.

--- ---

2. Update from the Secretariat

2.1 Nina Schwalbe, Managing Director, Policy and Performance, reported to the
EAC that the Secretariat has been working on updating the mission indicators
and that the Board has been provided with progress reports on Key
Performance Indicators and the GAVI All iance risk register.

GAVI Alliance Evaluation Advisory Committee Meeting, 2 June 2010 FINAL MINUTES


1

GAVI Alliance Evaluation Advisory Committee Meeting
2 June 2010
Teleconference

FINAL MINUTES

Finding a quorum of members present 1, the meeting commenced at 15.15 Geneva
time on 2 June 2010.

Given the length of the documents, the Chair of the Evaluati on Advisory Committee
(EAC) propose d that each committee member review the main report and the report
from one of the four strategic goals, along with their fellow committee member as
indicated.

? Strategic Goal 1: Sania Nishtar and Bernhard Schwartlander
? Strategic Goal 2: Stan Foster and Ken Hill
? Strategic Goal 3: George Wellde and Gonzalo Hernandez
? Strategic Goal 4: Minister Sezibera and Zenda Ofir

The Committee Chair suggested focusing on the following questions:
1. To what extent is there adequate descrip tion of the methods used in the
evaluation study?
2. To what extent is there adequate identification and assessment of the
limitations and potential sources of bias in the evaluation study?
3. To what extent do the reports adequately address the study?s defined
evaluation questions?
4. To what extent are the conclusions substantiated by the evaluation?s findings,
and supported through sound and transparent application of appropriate
evaluation methods?

Discussion followed:
1 IFFIm Evaluation

? It was noted that the report for Strategic Goal #3 contains an extensive
discussion of the IFFIm and AMC . The Secretariat is prepared to go to tender
with a Request for Proposals for an evaluation of the IFFIm once the steering
committee for this evaluation is convened and app roves the terms of
reference.

? Although the p reliminary draft report from the Second GAVI Evaluation is not
complete , the section on the IFFIm is almost final. W e could therefore
compare what is addressed in the Second GAVI Evaluation vis -a-vis IFFIm
wit h what we want to get out of the IFFIm evaluation as per the draft ToRs .
The EAC could then ask the IFFIm donors and other stakeholders whether we
have already learned what we wanted to learn about the IFFIm and, if not,
whether the best way to address ou tstanding questions related to the IFFIm is
1 Attendees are listed in Attachment A.

1


GAVI Alliance Programme and Policy Committee Meeting

17-18 February 2010
Geneva, Switzerland

Final Minutes

The meeting commenced 1 at 09.09 Geneva time on 17 February 2010. The PPC will
continue in its present form until the Governance Committee convenes in March, at which
time the membership, including the Chair, will be reconstituted and a new chair appointed.
The Chair summarised the key issues from the November board meeting and noted those
issues requiring follow up by the PPC.

DECISION
The GAVI Alliance Programme and Policy Committee:
Approved the minutes of its meetings on:
? 2 February 2009
? 17 February 2009
? 15-16 April 2009
? 4 June 2009
? 1-2 October 2009

1 Update from the Secretariat
Nina Schwalbe, Managing Director, Policy and Performance provided a summary of key
activities completed since the prior meeting and priorities and plans for 2010 including the
AMC, Board-level committee meetings, upcoming events and ongoing evaluations.
Discussion followed:
? The difference between the PPC and Secretariat Task teams was discussed. For
Secretariat task teams, the Secretariat defines the membership and the terms of
reference. A PPC task team requires PPC approval of membership and TORs. A
request was made for developing country representation on all task teams.
? Industry raised a question on the impact of the eligibility and graduation on the AMC. It
was noted that a meeting was being planned to discuss this with the AMC donors. A
comment was made that it is becoming more difficult to differentiate the subset of AMC
donors from the broader community of GAVI donors. The Secretariat was asked to
share any AMC materials with all donors rather than just the AMC donors.
? The Secretariat clarified that the approved investment cases for Yellow Fever from 2009-
2010 is US$ 44.8 million, for the Meningiti s stockpile from 2009-2013 is $55.1 million and
for the Meningitis A preventative (2009-2010) is $29.5 million. Any further decisions
regarding potential financing for these two vaccines will be determined as part of the
prioritisation process.
1 Attendees are listed in Attachment A.

GAVI Alliance Programme and Policy Committee Meeting, 18 -19 May 2010 FINAL MINUTES


1

GAVI Alliance Programme and Policy Committee Meeting
18 -19 May 2010
Geneva, Switzerland

Final Minutes

Finding a quorum of members present 1, the meeting commenced at 9.12 Geneva
time. The Programme and Policy Committee Chair Gustavo Gonzalez -Canali
exp ressed his vision to integrate the Committee?s technical discussions with a
strategic perspective to ensure Committee deliberations continue to be evidence
based, but accessible to a wider cross section of people. He asked committee
members to reflect on this issue and that of roles and responsibilities of the
committee.

The Chair welcomed Anne Schuchat, board representative for Research and
Technical Health Institutes, to her first in -person Committee meeting.

The Committee reviewed the minutes of its meeting on 17 -18 February, 29 March
and 16 April 2010 (Doc #1 in the committee pack).


DECISION
The GAVI Alliance Programme and Policy Committee:
Approved the minutes from 17 -18 February, 29 March and 16 April
2010.

1 Update from the Secretariat
Nina S chwalbe , Managing Director, Policy and Performance provided a summary of
key activities completed since the prior meeting and updated the Committee on
priorities/plans for the rest of 2010. She detailed Board -level committee meetings,
upcoming events, ong oing evaluations, and other key events for the information of
the Committee. Discussion including the following :

? The Evaluation Advisory Committee is actively providing guidance, advice and
input to the GAVI Phase 2 evaluation team. They are also spearhe ading the
development of the Terms of Reference (TOR?s) for the IFFIm evaluation. It is
hoped that the evaluation team will include a partner from a developing country.

? New AMC agreements have been signed. Provisional agreements were made
with Pfizer and full agreements with GSK. 13 Applications have already been
approved and will be supported through the AMC.

1 Participants are listed in Attachment A.

1



Board -2018 -Mtg -2-Doc 10h

Section A: Introduction
? The purpose of this paper is to respond to the request of the Gavi Alliance
Board to address transition challenges in high risk countries by requesting
the approval of post -transition support for Angola and Timor -Leste, based
on detailed country plans, as well as exceptionally approving that Congo?s
eligibility be determined on the latest GNI data .
? The implementation of the proposed country plans for Angola and Timor -
Leste would require an addition al US$ 10 million , in addition to the
US$ 20 million approved by the Board in June 2018 . The main cost driver
of the additional funding is the extension of some existing activities beyond
2020 in the next financing period (e.g. capacity building) and new ly identified
activities (e.g. polio transition in Angola or pneumococcal conjugate vaccine
(PCV ) and human papillomavirus vaccine ( HPV ) introductions in Timor -
Leste ). The PPC was supportive of this request.
? For Congo Repu blic, a costed country plan in line with the Board request
has also been developed. However, since then, critical information has
come to light regarding Congo Republic?s gross national income (GNI) per
capita. Data released in July 2018 shows that the cou ntry?s economy
continues to deteriorate and its 2017 GNI per capita decreased further to
US$ 1,360, the same as it was more than 10 years ago. While Congo?s
three -year GNI per capita average 1 remains just above Gavi?s eligibility
threshold, the latest GNI is significantly lower and represents the largest
decrease among Gavi countries. Furthermore, while the IMF projects
economic growth in Congo for 2018 , this growth would not be enough to
prevent the country from regaining Gavi eligibility in 2020. Therefor e, r ather
than approving post -transition support for 2019 and then Congo Republic
becoming Gavi -eligible in 2020, the PPC recommend s the Gavi Board to
exceptionally determine Congo Republic ?s eligib ility for 2019 on the latest
GNI data. As a result , the PPC recommended that Congo Republic become
eligible for Gavi support as of 1 January 2019 and that its health system
strengthening ( HSS ) grant ceiling be increased from US$ 4.5 million to
US$ 10 million (which is the amount the country needed as part of its post -
transition efforts ).

1 Gavi?s Eligibility and Transition Policy states countries are Gavi -eligible if their average GNI p.c.
over the past three years is equal to or below the threshold amount.
SUBJECT :
CONSENT AGENDA: POST -TRANSITION PLANS FOR
ANGOLA AND TIMOR -LESTE AND CONGO REPUBLIC ?S
ELIGIBILITY FOR GAVI SUPPORT
Agenda item: 10h
Category: For Decision
Report to the Board
28 -29 November 201 8

1


Re port to the Board



Annex A: Accelerating the equitable uptake and coverage of vaccines: Update on Gavi supported Vaccine
Programmes
Anne x A: Accelerating the equitable uptake and coverage of vaccines : Update on
Gavi supported Vaccine Programmes
1. Introduction
Gavi anticipates approximately 270 1 new vaccine introductions between
2016 and 20 20, a greater number than in any previous strategic period, with
a particularly high number expected in 2018. Over 4 0% of the se
introductions will be for non -routine programmes (e.g. Supplementary
Immunisation Activ ities , catch -up campaigns) . Over this strategic period,
Gavi expects to support 152 programme types.



1 This tally assumes that introductions for routine immunisation and multi -cohort campaigns for HPV
are counted as one event for a given country. NB: based on an alternate approach, the total
number of introductions, as reported to the PPC in May 2017, is more than 300 events 2 The count of 15 includes HPV (RI and MAC), IPV, JE, MSD, Meningitis A, MR, Pneumococcal,
Rotavirus, Yellow Fever and Pentavalent (10) routine programs and HPV demo, JE campaign,
Measles SIA/follow up, Meningitis A mini -catch -up, MR campaign.

1


Board -2017 -Mtg -1-Doc 07a

Report to the Board
14-15 June 2017

Section A: Summary
This update :
o Requests the Board to decide to continue support to Yemen despite the
country?s continuing defaulter status based on a recommendation by the
Programme and Policy Committee (PPC) (see under 1 in Section B) .
o Presents two programmatic challenges that were discussed by the PPC for
further guidance from the Board :
? balancing risk assurance with the need for timely and predictable HSIS
funding, and with ensuring country ownership and sustainability of
programmes (see under 2 in Section B) .
? sustaining progress in introducing pneumococcal and rotavirus
vaccines (see under 3 in Section B) .
o provides a high level cross -portfolio overview of PEF tier 1 countries?
performance (see under 4 in Section B) for the Boa rd?s information and
feedback.
A case study presenting Pakistan?s recent progress towards improving equitable
and sustainable immunisation coverage and describing how Alliance partners have
come together to support the country in reaching more children wit h vaccines is
provided in Doc 07b .
Detailed information on the Alliance?s in -country operations, activities,
achievements and challenges is provided in Annexes A through F. The PPC also
discussed the progress made on the implementation of the Country Enga gement
Framework ( Doc 03b to the May 2017 PPC) .
Section B: Alliance Update on Country Programmes
Improving sustainability of national immunisation programmes and
continued support to Yemen
1.1 As discussed in the Strategy Progress Update, 2016 was a record year in
terms of country co -financing for Gavi -supported programmes. However ,
Yemen is an exception to this trend, ha ving not been able to co -finance due
SUBJECT : COUNTRY PROGRAMMES : STRATEGIC ISSUES
Agenda item: 07a
Category: For Decision

Board -201 7-Mtg -1-Doc 00b




G avi Alliance Board Meeting
14 -15 June 2017
Intercontinental Hotel, Geneva, Switzerland

Monday 12 and Tuesday 13 June : Pre -Board meetings
Wednesday 14 June : 0 9.00 -17.30 (Board meeting Day One)
Thursday 15 June : 0 9.00 -16.00 (Board meeting Day Two)
Qu orum: 14


Agenda REVISED


Pre -Board Meetings ? Monday, 12 June 2017
Item Subject Room Schedule

? IFFIm Donors? meeting Moscou 13. 00 -15.30
? Audit and Finance Committee meeting Gavi Offices, 101 14.00 -18.00
? AMC Stakeholders? meeting Berne 16.00 -18.00


Pre -Board Meetings ? Tuesday , 13 June 2017
Item Subject Room Schedule

? Technical Briefing Session s
o Vaccine investment strategy
Break
o Immunisation in humanitarian settings
Ballroom AE 09.00 -12.30
09.00 -10. 30

11.00 -12.30
? Governance Committ ee meeting Londres 11.00 -13.00
Lunch Ballroom BC/
Foyer D
12. 30 -13. 30
? Technical Briefing Sessions (contd.)
o Health, climate change and environmental
impact of immunisation
Berne 13. 00 -14.30
13. 00 -14.30
? Developing Countries Board members meeting Ballro om AE 14.00 -15. 30
? All Chairs meeting Bruxelles 14. 30 -15. 30
? IFFIm Board meeting Moscou 15.30 -19.00
? Board Meeting: Closed session for Board
members and Alternate Board members
Ballroom AE 16.00 -19.00
? Unaffiliated Board members meeting Woods 19.15 -20. 15
? Gavi Donors? meeting Berne 19. 30 -21. 30

The official formal notification of the remaining AMC Offer Amount.